Watch CNBC's interview with Horizon Therapeutics CEO Tim Walbert

Horizon Therapeutics' stock is higher following news the FDA is to make an approval decision on the company's eye drug by March. Tim Walbert, Horizon Therapeutics CEO, joins CNBC's Meg Tirrell to discuss Horizon's new eye drug.
Mon, Dec 16 20192:13 PM EST